In addition, the use of selective cyclooxygenase-2 inhibitors poses a risk of ischemic heart disease (Hippisley-Cox and Coupland, 2005), and physicians hesitate to use them in patients with a history of cardiovascular disease. Here, PTGS2 is linked to coronary artery disorder.